10x almost right away. Full potential at least 100x. Compare, ultimately to alny or even to icpt or jazz. Of course, things need to go just right.
I am not a long here anymore and have quit looking in much. Did, however, stop by just now and I see that Max and Tall are still doing their vaudeville show of bashing this company between each other.
Since they don't intend to buy shares and have nothing but negative views, why do they continue with their nonsense? Dunno. Apparently neither of them has a real life.
That's not helpme_hanna. Look closely and u will see that the author of the lead post on this thread is
helprrne_hanna [that's r-n-e] I am helpme_hanna [that's m-e]
Must be careful. Helprne_hanna is NOT helpme_hanna. helpme_hanna is not hedge.risk or avi.morax.
The thing is, however, he is so enamored of Geert that he can't stand the idea that Geert might turn out to be his downfall. Rmsacc, Geert does have an apparently good resume but his company seems to be spinning its wheels and going nowhere--albeit in slow motion. It doesn't even appear to be trying.
Your love affair (figuratively speaking) with the ceo is likely to have been misplaced.
By the way, I sold two thirds of my stake today. I did okay, actually, because I had sold at 3.20 earlier and then bought back in at around 2.45.
You can be a bagholder if you want, not me.
$400,000 per month on average for q2 research and development. And that is a drop from from preceding quarters. How can we expect significant results from such small inputs?
Hey, I think the concept looks good and I like Geert's resume but there is no evidence that the company really intends to move this past the concept stage. Not at $400 k per month for r and d.
Maybe, and here's my hope at this stage, it is just a matter of treading water until Pfizer, Johnson& Johnson of some other buys the concept for, say, $250,000--and that would be generous.
Sure the "potential" is there but rxii does not seem intent on going after it.
hedge.risk, I agree with u that r&d is way too low. Lower than previous quarter. Really, r&d should be almost all the expenses for a company in this position. What else is there but research and development for a start-up biotech?
Worrisome! Is Geert really doing what everybody says he is doing, viz. moving the company forward?
I don't want to be negative but the more I look at the quarterly report, the less there is to be excited about.
Okay, I won't blow it out of proportion. You, biotechpicklist, are the one who suggested that the revenue from the specials could obviate to a significant degree the need for dilution. You have put the specials deal in the limelight a number of times.
Okay lottawatta, I'll take your word for it that the company said from day one that the EU deal is not expected to contribute anything significant to the bottom line. Guess I missed that.
I am still long (very long) this stock and I hope you are right about the market potential.
Hedge.risk, your post is very disingenuous. Everybody know and always knew that there would need to be lots of dilution. 14 million shares was never going to be enough to develop this company. Even with the LPC dilution, there would be way less than 20 million shares. Your scare tactics do not do credit to you. You are better than that.
The real question is: What, really, is the potential of this company? Not, will there need to be dilution to 20 million or more shares? The answer to the second question is, sure there will. Will it be worth it? A harder question to answer.
There was a "specials" provision entered into in Europe a few months ago. It was hoped, and expected by some, that significant cash would result. We now know that almost no revenue came in from the "specials" deal in Europe.
One possible negative from that is that the "unserved need" for the anti-scarring is no where near as great as we thought. Talk of one, two, three billion dollars a year market always sounded a little suspicious to me. Nobody ever said where those numbers came from. The failure of the "specials" deal in Europe might suggest that the numbers were just pie-in-the -sky wishful thinking.
In other words, u have no good reason to believe (as u say) that rxii will never get to market. U just say it for no reason.
Well, I do have good reason to say u should be ignored: U just say things for no good reason, except maybe to be contentious.
I hope you're right autumn, and you might well be. I have a ton of this stock now, much of it bought around 2.45. I will take some profits at about 3.20 but might also hold on to a core position.
Just as a point of information, exactly the same things were being said by the bulls when this was in the 6 range. Imagine if they had sold there and bought back at 2.50.
You're right, none of us have a crystal ball. All of us look at this in the light of what we want to happen, not necessarily what the evidence suggests will happen. I believe in technicals. They have made me $ in the past. I don't believe that rxii is immune from the technical indications.
Was a nice two or three day run. Now the retracement. This does not yet have legs and cannot break through the strong resistance zone it is in. If you like this stock and want some, wait until the retracement to 2.45.
This is not a stock to buy when it is in a rally--at least not until it shows a lot more strength and staying power.
Hold? Okay. Buy? At 2.45 or less. Sell? Okay at around 3.20.
We are in area of very strong resistance. It will not be easy to close above 3 and, if we do, we will have a tough slog almost to 4.
As for "volume never lies," look at May 2. 3m volume, intra-day dollar spike, closed flat, started swoon which lasted more than 3 months.
I hope things are different this time, and they might be, but two or three days of nice volume and slight price rise do not a trend reversal insure.
Despite you're dismissive post, winthrop.jefferson, genetherapyman is correct. This stock is near its fifty two week low and is down more than 60% from its 2014 high.
I am long and quite pleased with the latest indications that p2 will be reported as very successful. Still, I do not believe that ad hominem posts against somebody are warranted when what the person says--in this case, that the stock is way below its high for the year and has been weak in the market--is true.
I don't know if the reverse split has a lot to do with the plunge, as genetherapyman suggests, but that hypothesis is not implausible.
I agree hedge.risk. However, with the tiny float remaining, "meaningful volume" would not be huge. Just needs volume that is high relative to the average. 250,000 shares would be meaningful volume for rxii.
I base my technical views on the market close. This stock has some fairly significant intra-day moves but, lately, has ended the day at or very near 3. We'll see if today it breaks down and closes below 2.48. If it does, it would be a rather big negative.
Indicators starting to move north just a bit from way oversold condition. Bollinger bands are now very tight. A big move seems in the offing.
The last time there was such a long congestion line (about three weeks ago) I said that a big move was coming imminently. I said then that the indicators were mixed and that it was not possible from the charts to predict the direction of the move. It moved down 16.6% from 3 to 2.5. This time, all but one of the major indicators show a northen pointing from an oversold condition. Looks like the move will be up this time.
First resistance--and it looks fairly strong--will be at 3. Will need some retracement and rest at that point. An up move of .5 (from 2.5 to 3) would be a 20% move.